FLASCO / OPDIVO NCCN GUIDELINES UPDATE

FLASCO
May 15, 2015
Drugs

OPDIVO NCCN GUIDELINES UPDATE

Five days after the approval of OPDIVO for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, the National Comprehensive Cancer Network® (NCCN®) and their expert panel have made an interim update to the NCCN Guidelines® to include nivolumab (OPDIVO) as a Category 2A recommendation in this patient population.1 This interim update of the NCCN Guidelines supports the importance of this patient population having another treatment option.

If you would like to review this information, please click on the link below:

OPDIVO is associated with the following Warnings and Precautions including immune-mediated: pneumonitis, colitis, hepatitis, nephritis and renal dysfunction, hypothyroidism, hyperthyroidism, other adverse reactions; and embryofetal toxicity

For additional information, call 1 855 OPDIVO 1 (1 855 673 4861) Responses provided between 8:00 AM to 8:00 PM ET, Monday-Friday, or visit OPDIVO.com